← All indications
Fallopian Tube Neoplasms
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Phase 3 trials (53)
- thalidomide
- saracatinib
- acetylcarnitine
- rucaparib
- Nemvaleukin Alfa
- alvimopan
- atezolizumab
- olaparib
- urea
- binimetinib
- doxorubicin
- fluzoparib
- gemcitabine
- gen-1
- paclitaxel
- gl-onc1
- lapatinib
- phenoxodiol
- epirubicin
- nivolumab
- pembrolizumab
- octreotide
- omp-305b83
- oregovomab
- acetaminophen
- polyvalent antigen-klh conjugate vaccine
- ifosfamide
- carboplatin
- autologous dendritic cells
- topotecan
- +23 more
Phase 2 trials (218)
- allopurinol
- decitabine
- methylprednisolone
- mifepristone
- 7-hydroxystaurosporine
- cp-18
- urokinase-derived peptide a6
- Abagovomab
- abemaciclib
- anlotinib
- allogeneic natural killer cells
- alvac ny eso-1 vaccine
- rilotumumab
- amifostine
- anetumab ravtansine
- acetylcysteine
- astx660
- autologous tumor infiltrating lymphocytes
- avelumab
- mk-1775
- sorafenib
- belinostat
- epoetin
- talazoparib
- bryostatin
- irinotecan
- tlk286
- carboxyamidotriazole
- catumaxomab
- lenalidomide
- +188 more
Phase 1 trials (92)
- azacitidine
- adct-301
- autologous ny-eso-1-specific cd8-positive t lymphocytes
- bendamustine
- bone autograft
- bp1001
- cdx-301
- conatumumab
- coti2
- selinexor
- dsp-7888
- egen-001
- enoblituzumab
- genetically engineered ny-eso-1-specific t lymphocytes
- her2bi-armed activated t cells
- incomplete freund's adjuvant
- ketorolac
- khk2866
- montanide isa51
- multi-epitope folate receptor alpha peptide vaccine
- ss1(dsfv)pe38
- ny-eso-1 olp4
- onalespib
- cantrixil
- abexinostat
- trastuzumab
- propranolol
- sch-58500
- interleukin-12
- ny-eso-1 protein
- +62 more
Organizations
Organization Involved with Phase 3 Indications (94)
- Foundation Medicine
- Bristol-Myers Squibb
- Amgen
- Clovis Oncology
- Roche
- Schering-Plough
- AstraZeneca
- Merck
- Eli Lilly
- Novartis
- Array BioPharma
- Cubist
- Hengrui Therapeutics, Inc.
- Myrexis Inc.
- Oasmia Pharmaceutical AB
- PharmaMar
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- British Columbia Cancer Agency
- Medical Research Council
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Central South University
- Hebei University
- Canadian Cancer Trials Group
- Case Western Reserve University
- Cancer Research UK
- University of London
- Cornell University
- Grupo Español de Investigación en Cáncer de Ovario
- Guangxi Medical University
- +64 more
Organization Involved with Phase 2 Indications (123)
- Regeneron
- Daiichi Sankyo
- Seattle Genetics
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Genmab
- Imclone
- Morphotek
- Centocor
- Medivation
- Genentech
- Merck KGaA
- Genzyme
- Pfizer
- Sanofi
- Sanofi-Synthelabo
- Bayer
- Celsion
- GlaxoSmithKline
- Glycotope GmbH
- Gradalis, Inc.
- ImmunoVaccine Technologies, Inc.
- Merrimack Pharmaceuticals
- Valerio
- Oxford BioMedica
- AltaRex
- R-Pharm
- Recepta Biopharma
- Shenzhen SiBiono GeneTech Co.,Ltd
- +93 more
Organization Involved with Phase 1 Indications (35)
- ADC Therapeutics SARL
- Incyte
- Abbott
- Genelux
- Acetylon Pharmaceuticals Incorporated
- Biomarin
- Intrexon
- Boston Biomedical
- Eisai
- Sanofi-Aventis
- Wyeth
- Atara Biotherapeutics
- Bio-Path Holdings, Inc.
- Celldex Therapeutics
- Kyowa Hakko Kirin
- Mereo BioPharma
- Ozmosis Research Inc.
- Oncolix, Inc.
- Transgene
- TetraLogic Pharmaceuticals
- Advent Health
- Johns Hopkins University
- Northwell Health
- Southern Illinois University
- University of Michigan
- Xencor
- Lee's Pharmaceutical
- Women's Cancer Center - Los Gatos
- ICON
- Cotinga Pharmaceuticals
- +5 more
Organization Involved with Other Experimental Indications (2)